F2G Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Private

  • Employees
  • 82

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 19

F2G General Information

Description

Developer of a biotech therapeutic designed to treat rare and life-threatening fungal infections. The company's technology offers a new class of antifungal agents called orotomides that selectively target enzymes in the pyrimidine biosynthesis pathway, proprietary genomics for pathogen identification, and oral formulations for long-term treatment, enabling medical professionals to treat resistant fungal mold infections that affect the immune system.

Contact Information

Website
www.f2g.com
Formerly Known As
Functional Fungal Genomics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Lab B Ground Floor Block 50
  • Alderley Park, Nether Alderley, Cheshire
  • Macclesfield SK10 4TG
  • England, United Kingdom
+44 0161
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • Lab B Ground Floor Block 50
  • Alderley Park, Nether Alderley, Cheshire
  • Macclesfield SK10 4TG
  • England, United Kingdom
+44 0161

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

F2G Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Secondary Transaction - Private Completed Clinical Trials - Phase 2
14. Later Stage VC 12-Sep-2024 Completed Clinical Trials - Phase 2
13. Later Stage VC 04-Aug-2022 Completed Clinical Trials - Phase 2
12. Grant 01-Jan-2022 Completed Clinical Trials - Phase 2
11. Later Stage VC (Series G) 12-Aug-2020 Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private Completed Clinical Trials - Phase 2
9. Later Stage VC (Series F) 01-Nov-2019 Completed Clinical Trials - Phase 2
8. Debt - General 22-Nov-2018 Completed Clinical Trials - Phase 1
7. IBO 29-Aug-2018 $103M Completed Clinical Trials - Phase 1
6. Grant 01-Aug-2017 $1.32M $103M Completed Clinical Trials - Phase 1
To view F2G’s complete valuation and funding history, request access »

F2G Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series H1 Convertible Preferred
Series G Convertible Preferred
Series G Convertible Preferred
Series F Convertible Preferred
Series F Convertible Preferred
Series E Convertible Preferred 12,531,330 $0.013086 $1.74 $1.74 $1.74 5.32%
Series D 5,000,000 $0.013086 $1.57 $1.57 $1.57 2.12%
To view F2G’s complete cap table history, request access »

F2G Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotech therapeutic designed to treat rare and life-threatening fungal infections. The company's technolo
Drug Discovery
Macclesfield, United Kingdom
82 As of 2023

Malvern, PA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

F2G Competitors (48)

One of F2G’s 48 competitors is Venatorx Pharmaceuticals, a Venture Capital-Backed company based in Malvern, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Venatorx Pharmaceuticals Venture Capital-Backed Malvern, PA
Genentech Formerly VC-backed South San Francisco, CA
GMAX Bio Venture Capital-Backed Hangzhou, China
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 48 competitors. Get the full list »

F2G Patents

  • 163

    Total Documents Applications and Grants

  • Total Patents Families

  • 65

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

F2G Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11819503-B2 Method of treating coccidioides infection Active 23-Apr-2019
US-20200338072-A1 Method of treating coccidioides infection Active 23-Apr-2019
GB-201719873-D0 Pharmaceutical formulation Inactive 29-Nov-2017
EP-3463365-B1 Antifungal pharmaceutical formulation Active 25-May-2016
AU-2017270942-A1 Pharmaceutical formulation Active 25-May-2016 A61K9/0053
To view F2G’s complete patent history, request access »

F2G Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

F2G Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
AMR Action Fund Impact Investing Minority
Blue Owl Capital Asset Manager Minority
ICG PE/Buyout Minority
Johnson & Johnson Corporation Minority
Pfizer Corporation Minority
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial

F2G FAQs

  • When was F2G founded?

    F2G was founded in 1998.

  • Where is F2G headquartered?

    F2G is headquartered in Macclesfield, United Kingdom.

  • What is the size of F2G?

    F2G has 82 total employees.

  • What industry is F2G in?

    F2G’s primary industry is Drug Discovery.

  • Is F2G a private or public company?

    F2G is a Private company.

  • What is F2G’s current revenue?

    The current revenue for F2G is .

  • How much funding has F2G raised over time?

    F2G has raised $273M.

  • Who are F2G’s investors?

    AMR Action Fund, Blue Owl Capital, ICG, Johnson & Johnson, and Pfizer are 5 of 19 investors who have invested in F2G.

  • Who are F2G’s competitors?

    Venatorx Pharmaceuticals, Genentech, GMAX Bio, Inovio Pharmaceuticals, and Gilead are some of the 48 competitors of F2G.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process